Literature DB >> 23026821

EGFR mutations in circulating tumour DNA.

Rafael Rosell1, Miguel Angel Molina, María Jose Serrano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23026821     DOI： 10.1016/S1470-2045(12)70369-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  12 in total

Review 1.  Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Authors:  Niki Karachaliou; Aaron E Sosa; Miguel Angel Molina; Margarita Centelles Ruiz; Rafael Rosell
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 2.  Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.

Authors:  David Pérez-Callejo; Atocha Romero; Mariano Provencio; María Torrente
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 3.  Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

Authors:  Silvia Calabuig-Fariñas; Eloísa Jantus-Lewintre; Alejandro Herreros-Pomares; Carlos Camps
Journal:  Transl Lung Cancer Res       Date:  2016-10

4.  Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.

Authors:  Cecile Bosc; Gilbert R Ferretti; Jacques Cadranel; Clarisse Audigier-Valette; Benjamin Besse; Fabrice Barlesi; Chantal Decroisette; Sylvie Lantuejoul; François Arbib; Denis Moro-Sibilot
Journal:  Target Oncol       Date:  2014-08-15       Impact factor: 4.493

5.  Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.

Authors:  Tianhong Li; Bilal Piperdi; William V Walsh; Mimi Kim; Laurel A Beckett; Rasim Gucalp; Missak Haigentz; Venu G Bathini; Huiyu Wen; Kaili Zhou; Patricia B Pasquinelli; Srikanth Gajavelli; Meera Sreedhara; Xianhong Xie; Primo N Lara; David R Gandara; Roman Perez-Soler
Journal:  Clin Lung Cancer       Date:  2016-10-28       Impact factor: 4.785

Review 6.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

Authors:  Marius Ilie; Véronique Hofman; Elodie Long; Olivier Bordone; Eric Selva; Kevin Washetine; Charles Hugo Marquette; Paul Hofman
Journal:  Ann Transl Med       Date:  2014-11

7.  Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.

Authors:  M Teresa Agulló-Ortuño; Inmaculada García-Ruiz; C Vanesa Díaz-García; Ana B Enguita; Virginia Pardo-Marqués; Elena Prieto-García; Santiago Ponce; Lara Iglesias; Jon Zugazagoitia; José A López-Martín; Luis Paz-Ares; Juan A Nuñez
Journal:  Cancer Chemother Pharmacol       Date:  2019-12-12       Impact factor: 3.333

Review 8.  Therapy of advanced squamous cell carcinoma of the skin.

Authors:  Claudia Bejar; Eve Maubec
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 9.  Targeting EGFR in Lung Cancer: Current Standards and Developments.

Authors:  Asunción Díaz-Serrano; Pablo Gella; Elisabeth Jiménez; Jon Zugazagoitia; Luis Paz-Ares Rodríguez
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

10.  Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).

Authors:  Dario de Biase; Michela Visani; Umberto Malapelle; Francesca Simonato; Valentina Cesari; Claudio Bellevicine; Annalisa Pession; Giancarlo Troncone; Ambrogio Fassina; Giovanni Tallini
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.